Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study

Edoardo Conticini1 · Miriana d’Alessandro2 · Silvia Grazzini1 · Marco Fornaro3 · Daniele Sabella3 · Giuseppe Lopalco3 · Federico Giardina4 · Serena Colafrancesco5 · Chiara Rizzo5 · Giuliana Guggino5 · Roberta Priori4 · Fabrizio Conti4 · Florenzo Iannone3 · Elena Bargagli2 · Luca Cantarini1 · Bruno Frediani1

Received: 31 March 2022 / Accepted: 6 June 2022 / Published online: 26 June 2022 © The Author(s) 2022

Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination plays a crucial role as pivotal strategy to curb the coronavirus disease-19 (COVID-19) pandemic. The present study described the clinical status of patients affected by idiopathic inflammatory myopathies (IIM) after COVID-19 vaccination to assess the number of relapses. We included all patients affected by IIM and followed by Myositis Clinic, Rheumatology and Respiratory Diseases Units, Siena University Hospital, Bari University Hospital, Policlinico Umberto I, Sapienza University, Rome, and Policlinico Paolo Giaccone, Palermo. They underwent a telephone survey. A total of 119 IIM patients (median, IQR 58 (47–66) years; 32 males; 50 dermatomyositis, 39 polymyositis and 30 anti-synthetase syndrome) were consecutively enrolled. Except four patients who refused the vaccination, 94 (81.7%) received Comirnaty, 16 (13.9%) Spikevax, 5 (4.4%) Vaxzevria. Seven (6.1%) patients had flare after vaccination. One of them had life-threatening systemic involvement and died two months after second dose of COVID-19 vaccination. From logistic regression analysis, Chi2-log ratio = 0.045, the variable that most influences the development of flare was the number of organs involved (p = 0.047). Sixty-eight patients received the third dose of COVID-19 vaccination: 51 (75%) Comirnaty and 17 (25%) Moderna. No patients had flares after third dose. Our study represents the largest cohort of IIM patients in which the incidence of recurrence after anti-SARS-CoV-2 vaccine was assessed. In line with real-life data from other diseases, we found a clinical non-statistically significant risk of relapse in our patients, which occurred seldom, usually mild and in patients with a more severe and aggressive course of disease.

Keywords COVID-19 vaccination · Idiopathic inflammatory myopathies · Relapses

Abbreviations
COVID-19 Coronavirus disease-19
IIM Idiopathic inflammatory disease
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

Significance and innovation

- This is first of the studies to look at flares following COVID-19 vaccination longitudinally in idiopathic inflammatory myopathies multicentre cohort
- Clinical non-statistically significant risk of relapse in idiopathic inflammatory myopathies patients was found
- The risk of relapse after COVID-19 vaccination occurred seldom, and were usually mild and in patients with a more severe and aggressive course of disease.
Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination plays a crucial role as a pivotal strategy to curb the coronavirus disease-19 (COVID-19) pandemic. The use of recently developed mRNA vaccines, such as BNT162b2 (Pfizer) [1], and mRNA-1273 (Moderna) [2], and ChAdOx1-S (AstraZeneca) adenovirus vaccine [3], has provided effective protection against severe COVID-19. mRNA vaccines use lipid nanoparticles as a vehicle to deliver genetically modified mRNA. Once injected, the mRNA is translated into target protein resulting in robust immune response. To date, an excellent safety profile has been found for these vaccines [4] and severe reactions occur seldom.

Idiopathic inflammatory myopathies (IIM) constitute a heterogeneous group of myopathies characterized by immune-mediated inflammation of the striate muscle and an altered immune system [5]. In patients affected by such diseases, COVID-19 vaccination may cause an underlying inflammatory disease to flare or reduce immune responses.

Despite the mass-scale COVID-19 vaccination, literature data about the incidence of disease flares in IIM patients is not still reported as well as the immunological responses condition.

The present study aimed to describe the clinical status of patients affected by IIM after vaccination against COVID-19 to assess the number of relapses in a cohort of Italian patients with such disease.

Methods

Study population

We included all patients affected by IIM and followed by Myositis Clinic, Rheumatology and Respiratory Diseases Units, Siena University Hospital, Bari University Hospital, Policlinico Umberto I, Sapienza University, Rome, and Policlinico Paolo Giaccone, Palermo.

Inclusion criteria were a recent (< 3 months) clinical and serological assessment before the survey and the fulfillment of 2017 American College of Rheumatology/European League against Rheumatisms (ACR/EULAR) classification criteria for patients affected by Dermatomyositis (DM) and Polymyositis (PM) [6]; conversely, for patients affected by Anti-synthetase syndrome (ASS), due to the lack of validated criteria, inclusion criteria were positivity of any anti-synthetase antibody and a diagnosis performed by a physician with an expertise in the field of IIM.

Exclusion criteria were a diagnosis of inclusion body myositis (IBM), the non-completion of anti-SARS-CoV-2 vaccine cycle and the lack of a recent (< 3 months) assessment before survey.

All patients included in the study underwent a telephone survey to establish their clinical status and potential relapses after vaccination. When applicable, patients were evaluated in the outpatient clinic, as part of our clinical practice. When it was not possible (e.g. patient in full remission or living far from our centers, evaluated on a 6-month-based routine), patients’ data were collected by telephone interview.

The following data were collected: age, sex, definite diagnosis, antibodies, length of disease, number of organs involved, myositis damage index (MDI), physician global assessment (PhGA) in Likert scale, serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), creatine kinase (CK), myoglobin and aldolase, treatment at the time of vaccination, including glucocorticoids (GCs) dosage, type of anti-SARS-CoV-2 vaccine, the onset of flare after vaccination, its type and severity (graded as mild, minor, major and life-threatening) and the change in medications after the flare. Flare was defined as worsening of MMT-8 by ≥ 20% or extra-muscular organ disease activity worsening by ≥ 2 cm on a 10-cm VAS or any of the IMACS CSMs worsening by ≥ 30% [7, 8] occurring within 30 days from vaccination against COVID-19.

All patients gave their written informed consent to participation in the study.

Statistical analysis

We expressed all values as medians [interquartile ranges (IQRs)] or numbers (%). For categorical variables, we applied Fisher’s exact or Chi-squared tests to compare proportions between groups, and the Mann–Whitney U-test to compare medians. We applied logistic regression analysis to identify variables associated with flare after COVID-19 vaccination and the calculated odds ratio (OR), 95% confidence interval (CI), and P values. A p value less than 0.05 was considered statistically significant. Statistical analysis was performed by GraphPad Prism 9.3 and XLSTAT 2021 software.

Results

A total of 115 IIM patients (median, IQR 58 (47–66) years; 30 males) were consecutively enrolled. Forty-eight had a diagnosis of DM, 37 had PM and 30 had ASS. The median months of disease duration was 79.62 ± 83.98. According to the extent of disease, thirty-six had only one organ or system involved, 45 had two, 22 had three, 11 had four and one had five.
The majority of them received two doses of COVID-19 vaccine, except four patients who refused the vaccination: 94 (81.7%) were vaccinated with Comirnaty (Pfizer BioNTech), 16 (13.9%) with Spikevax (Moderna), 5 (4.3%) with Vaxzevria (AstraZeneca). Seven (6.1%) patients had flare after vaccination, most of them were mild except one major with three organs involved and one life-threatening systemic involvement who died after two months from second dose of vaccination.

Table 1 shows demographic, clinical and immunological data in the two groups divided according to the development of flare after two doses of COVID-19 vaccination.

Clinical and demographic features of patients who had flare after second dose of vaccination against COVID-19 are reported in Table 2.

To understand or predict the effect of demographic (gender, age) and clinical (number of organs involved, length of diseases, CPK values and disease activity) features on the flare development after vaccination, a logistic regression analysis was performed (Table 3).

The goodness-of-fit statistics showed a Chi² associated with the Log ratio (LR) of 0.045 (Fig. 1a). From the probability associated with the Chi-square tests, the Type II analysis showed the variable that most influences the development of flare was the number of organs involved (p = 0.047). The ROC curve of the logistic regression model showed an AUC of 0.881 (Fig. 1b). Accordingly, the classification table for the training sample (confusion matrix) and confusion plot was performed (Fig. 2). The control group (patients w/o flare after vaccination) was well classified at 100% while patients who developed flare after vaccination were well classified at 50%.

Sixty-eight patients received the third dose of COVID-19 vaccination: 51 (75%) Comirnaty and 17 (25%) Spikevax. No patients had flares after the third dose of vaccination against COVID-19.

**Discussion**

The approval of several vaccines against SARS-CoV-2 has dramatically changed perspectives of the global struggle against COVID-19. Such vaccines have provided, both in registrative studies [9] and in preliminary real-life evidence [10, 11], an overall good efficacy and safety.

Statistically significant reduction of death and hospitalization emerged in subjects completed 3-dose vaccination courses to those non-vaccinated [12]. Analogously, no relevant adverse events have been generally reported. Although registries studies related to COVID-19 vaccination did not include patients affected by severe autoimmune diseases, after roughly one year after the start of the global vaccination campaign, a growing number of real-life data is available about efficacy and safety of anti-SARS-CoV-2 vaccines in patients affected by severe rheumatic disorders [13–15].

The very first evidence came from case reports or small case series, reporting the onset of autoimmune inflammatory disorders in previously healthy subjects or their relapse in patients considered in remission or in low disease activity [16].

The most common rheumatic adverse events in healthy subjects, aside from arthralgias, are seronegative arthritis [17], polymyalgia rheumatica [17, 18] and skin, urticarial or leukocytoclastic, vasculitis [19–21]. Specifically focusing on IIM, only scanty data are available: 5 papers, for a sum of 8 patients [22–26] mentioned the occurrence of myositis after vaccination and in all of them the course of disease was favorable, with an overall good response to treatment. Notably, in 3 of them a concomitant anti-SAE or anti-Pm/Scl 75 positivity was assessed.

Nevertheless, vaccines seem to be a safe option in rheumatic patients, as large studies, performed in wide cohorts, have not shown any significant risk of relapse in this particular subset of patients [27–30], even when affected by rare diseases [31, 32].

In line with these findings, there is a paucity of data for patients with a previous diagnosis of IIM who subsequently underwent anti-SARS-CoV-2 vaccine. To the best of our knowledge, roughly 100 myositis patients, coming from multicenter studies [14, 27, 28, 32–35], were included in studies focusing on vaccine safety, while others, although larger, did not include IIM [29, 36].

Moreover, only two papers specifically assessed the risk of flares among these patients [27, 28], while none of them stratified patients according to disease activity, number of organs involvement, current and previous treatments nor assessed risk of flares after booster doses.

Efficacy of anti-SARS-CoV-2 vaccines in specific categories of patients, due to the lack of validated diagnostic procedures, has been even less assessed; nonetheless, a good protection from severe forms of COVID-19 seems to be provided also in patients affected by rheumatic diseases [37] in general and IIM in particular [38], despite a lower rate in seroconversion in subjects treated with anti-CD20 and anti-CTLA-4 agents [39, 40].

To the best of our knowledge, ours represent the largest cohort of IIM patients in which the incidence of recurrence after anti-SARS-CoV-2 vaccine was assessed. Moreover, in our study, we specifically assessed disease extent, activity and damage, as well as the autoimmune profile and the concomitant immunosuppressive treatment, to assess which patients were more prone to suffer from disease relapse. Finally, ours is the first study to assess the incidence of recurrence after the “booster” dose of
Table 1  Clinical, demographic and immunological features of IIM patients at the time of COVID-19 vaccination

| Parameters                          | Flare after two doses (n = 7) | No-flare after two doses (n = 108) | p value |
|-------------------------------------|-------------------------------|-----------------------------------|---------|
| **Age (years)**                     | 55 (51–68)                   | 59 (47–67)                        | NS      |
| **Gender (male/female)**            | 2/5                           | 28/80                             | NS      |
| **Diagnosis (n, %)**                |                               |                                   |         |
| DM                                  | 2 (29%)                       | 46 (43%)                          | NS      |
| PM                                  | 2 (29%)                       | 35 (32%)                          | NS      |
| ASS                                 | 3 (42%)                       | 27 (25%)                          | NS      |
| **Antibodies (n, %)**               |                               |                                   |         |
| Jo1                                 | 2 (29%)                       | 25 (23%)                          |         |
| PL7                                 | –                             | 3 (3%)                            |         |
| PL12                                | –                             | 1 (0.9%)                          |         |
| Ku                                  | –                             | 2 (2%)                            |         |
| Mi2                                 | 1 (14%)                       | 7 (6.5%)                          |         |
| PM/Sc1                              | 1 (14%)                       | 5 (4.6%)                          |         |
| Ro52                                | 1 (14%)                       | 7 (6.5%)                          |         |
| TIG1g                               | –                             | 5 (4.6%)                          |         |
| MD5A                                | –                             | 6 (5.5%)                          |         |
| SRP                                 | –                             | 1 (0.9%)                          |         |
| SAE                                 | –                             | 2 (2%)                            |         |
| cN1a                                | –                             | –                                 |         |
| NPX                                 | –                             | 1 (0.9%)                          |         |
| SSA                                 | –                             | 12 (11%)                          |         |
| Ds-DNA                              | –                             | 1 (0.9%)                          |         |
| ANA (only positivity)               | –                             | 3 (3%)                            |         |
| **Negative**                        | 2 (29%)                       | 27 (25%)                          |         |
| **Length of disease (months)**      | 88.62 ± 105.02                | 78.35 ± 82.58                     | NS      |
| **Number of organs involved (n, %)**|                               |                                   | 0.0004  |
| One                                 | 0                             | 36 (33%)                          |         |
| Two                                 | 2 (29%)                       | 43 (40%)                          |         |
| Three                               | 3 (43%)                       | 19 (18%)                          |         |
| Four                                | 1 (14%)                       | 10 (9%)                           |         |
| Five                                | 1 (14%)                       | 0                                 |         |
| **Type of vaccination (n, %)**      |                               |                                   | NS      |
| Comirnaty                           | 6 (86%)                       | 88 (81%)                          |         |
| Spikevax                            | 1 (14%)                       | 15 (14%)                          |         |
| Vaxzevria                           | 0                             | 5 (5%)                            |         |
| **Disease activity (n, %)**         |                               |                                   | NS      |
| PhGA ≥ 2                            | 3 (43%)                       | 27 (25%)                          |         |
| PhGA < 2                            | 4 (57%)                       | 81 (75%)                          |         |
| MDI                                 | 3 (1–6.5)                     | 2 (1–4)                           | NS      |
| CRP (mg/dL)                         | 0.1 (0.01–0.3)                | 0.99 (0.3–2.9)                    | 0.0041  |
| ESR                                 | 32 (14–39)                    | 15.5 (8–27.5)                     | NS      |
| CPK                                 | 111 (63–905)                  | 97.5 (63–158)                     | NS      |
| **Treatment at time of vaccination (n, %)** |                               |                                   | NS      |
| GCs                                 | 0                             | 10 (9%)                           |         |
| Immunosuppressive                   | 3 (43%)                       | 19 (18%)                          |         |
| Biologic                            | 1 (14%)                       | 2 (2%)                            |         |
| Combination                         | 3 (43%)                       | 65 (60%)                          |         |
| No-treatment                        | –                             | 12 (11%)                          |         |

Fisher’s exact or Chi-squared tests were used to compare proportions of gender, diagnosis, organ involvement, type of vaccination, disease activity and treatment. Mann–Whitney U test analysis was used to compare medians.

ASS anti-synthetase syndrome, DM dermatomyositis, PM polymyositis, PhGA physician global assessment, MDI myositis damage index, CRP C-reactive protein, ESR erythron with sedimentation, CPK creatin phosphokinase, GCs glucocorticoids.
anti-SARS-CoV-2 vaccine, which has now gained a paramount role in the protection against “Omicron” variant [10].

In our cohort, only a minority of patients (7 out of 115) suffered from any relapse after the first two doses of vaccine and only one of them had a major flare of disease. Similarly, an even lower incidence of flare was evidenced in those patients who underwent “booster” dose of vaccine: a further disease relapse was assessed only in the one who suffered from a major flare after the second dose.

Stratifying our patients according to the flare after COVID-19 vaccination, the number of organs involved, and CRP values were statistically different. Assessing logistic regression analysis only the number of organs and systems could affect flare after COVID-19 vaccination: that means that patients with a more severe and aggressive disease, namely the ones with extra-muscular involvement, may be more prone to suffer from IIM flare, presumably due to the incidence of recurrence after COVID-19 vaccination burden and to a less controlled disease.

On the other hand, such patients are the ones who, due to the overall systemic involvement, namely the respiratory tract one, and the prolonged immunosuppression status, have the worst outcome in case of COVID-19 pneumonia [41]: for this reason, also in this subset of patients, anti-SARS-CoV-2 vaccination should be strongly suggested nor delayed.

Despite the contribution of our study to evaluate the safety of vaccination against COVID-19 in IIM patients, we did not analyze the rate of recurrence after COVID-19. Further studies should be performed to assess the occurrence of myositis relapses in COVID-19 and their optimal management.

In conclusion, we evidenced a good safety profile of anti-SARS-CoV-2 vaccine in a large cohort of patients affected by IIM. Our findings, which are in line with real-life data coming from patients with other diseases, have found a clinical non-statistically significant risk of relapse in our patients, which occurred seldom, usually mild and in the ones with a more severe and aggressive course of disease: indeed, the only patient who died suffered from a severe, long-standing PM poorly responsive to the treatment. Such findings are comparable with the literature data available about other rheumatologic disorders [30, 42].

### Table 2
Clinical and demographic data of IIM patients who had flare after second dose of vaccination against COVID-19, including age, gender type of vaccination, diagnosis, number of organs involved, treatment at the time of vaccination, severity of flare, type of flare, change in medication and outcome.

| Parameters                        | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
|-----------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Age (years)                       | 28        | 42        | 47        | 55        | 68        | 52        | 51        |
| Gender (M/F)                      | F         | F         | Comirnaty | Comirnaty | Comirnaty | Comirnaty | Comirnaty |
| Type of Vaccination               | Moderna   | Comirnaty | Comirnaty | Comirnaty | Comirnaty | Comirnaty | Comirnaty |
| Diagnosis                         | PM        | ASS       | ASS       | DM        | PM        | PM        | DM        |
| Number of organs involved         | Muscle    | Skin and joint | Muscle | Muscle, skin, lung and GI | Muscle | Muscle and lung | Muscle and skin |
| Treatment at the time of vaccination | IVIG     | GCs, MTX, RTX | MTX    | GCs and MTX | MMF     | RTX, Tacrolimus and GCs | GCs and MTX |
| Severity of flare                 | Mild      | Mild      | Major     | Mild      | Mild      | Mild      | Mild      |
| Type of flare                     | Muscle    | Muscle    | Muscle, heart and GI | Skin     | Muscle | Life-threatening Macrophage activation syndrome | Muscle |
| Change in medication              | No        | Yes       | Yes       | Yes       | No        | Yes       | No        |
| Outcome                           | Resolved  | Resolved  | Resolved  | Resolved  | Resolved  | Death     | Resolved  |

### Table 3
Results of logistic regression analysis for the development of flare after two doses of COVID-19 vaccination.

| Parameters                        | OR   | 95% CI   | p value |
|-----------------------------------|------|----------|---------|
| Men (vs women)                    | 0.66 | 0.04–10.83 | 0.770   |
| Age (years)                       | 0.91 | 0.79–1.06 | 0.227   |
| Number of organs involved         | 5.77 | 1.03–32.44 | 0.047*  |
| Length of diseases (months)       | 1.00 | 0.99–1.01 | 0.179   |
| Disease activity (PhGA ≥ 2)       | 1.67 | 0.56–3.99 | 0.116   |
| CPK                               | 1.003 | 1–1.005 | 0.061   |

*p < 0.05
**Funding** Open access funding provided by Università degli Studi di Siena within the CRUI-CARE Agreement. No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

**Data availability** The data presented in this study are available on request from the corresponding author.

**Declarations**

**Conflict of interest** The authors declare no conflicts of interest.

**Ethics** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee (C.E.A.V.S.E. OSS_REOS n° 12908; Markerlung 17431; Rhelabus 22271).

**Informed consent** Informed consent was obtained from all subjects involved in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615. https://doi.org/10.1056/NEJMoa2034577

2. Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416. https://doi.org/10.1056/NEJMoa2035389
3. Voysey M, Clemens SAC, Madhi SA et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99–111. https://doi.org/10.1016/S0140-6736(20)32366-1

4. Mascellino MT, Di Timoteo F, De Angelis M, Oliva A (2021) Overview of the main anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist 14:3459–3476. https://doi.org/10.2147/IDR.S315727

5. Pinto B, Janardana R, Nadig R et al (2019) Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies, Clin Rheumatol 38:1931–1934. https://doi.org/10.1007/s10067-019-04512-6

6. Lundberg IE, Tjärnlund A, Bottai M et al (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468

7. Rider LG, Aggarwal R, Machado PM et al (2018) Update on outcome assessment in myositis. Nat Rev Rheumatol 14:303–318. https://doi.org/10.1038/nrrheum.2018.33

8. Rider LG, Werth VP, Huber AM et al (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 63(Suppl 11):S118–157. https://doi.org/10.1002acr.20532

9. COVID-19 Studies from the World Health Organization Database-ClinicalTrials.gov. https://clinicaltrials.gov/ct2/who_table. Accessed 7 Feb 2022

10. EMA (2022) Preliminary data indicate COVID-19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant. In: European Medicines Agency. https://www.ema.europa.eu/en/news/preliminary-data-indic-covid-19-vaccines-remain-effective-against-severe-disea-se-hospitalisation. Accessed 7 Feb 2022

11. Zheng C, Shao W, Chen X et al (2022) Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis 114:252–260. https://doi.org/10.1016/j.ijid.2021.11.009

12. Thompson MG (2022) Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalisations among adults during periods of delta and omicron variant predominance—VISION network. 10 states, August 2021–January 2022. MMWR Morb Mortal Wkly Rep. https://doi.org/10.15585/mmwr.mm7104e3

13. EULAR | EULAR Sars Cov 2 vaccination rmd patients. https://www.eular.org/eular_sars_cov_2_vaccination_rmd_patients.cfm. Accessed 7 Feb 2022

14. Geisen UM, Berner DK, Tran F et al (2021) Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 80:1306–1311. https://doi.org/10.1136/annrheumdis-2021-220722

15. Sen P, Gupta L, Lilleker JB et al (2022) COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatol Int 42:23–29. https://doi.org/10.1007/s00296-021-05046-4

16. Conticini E, d’Alessandro M, Bergantini L et al (2021) Relapse of microscopic polyangiitis after vaccination against COVID-19: a case report. J Med Virol 93:6439–6441. https://doi.org/10.1002/jmv.27192

17. Ursini F, Ruscitti P, Raimondo V et al (2021) Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-221587

18. Ottaviani S, Juge P-A, Forien M et al (2021) Polymyalgia rheumatica following COVID-19 vaccination: a case-series of ten patients. Jt Bone Spine 89:105334. https://doi.org/10.1016/j.jbspin.2021.105334

19. Gambichler T, Boms S, Susok L et al (2022) Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol 36:172–180. https://doi.org/10.1111/jdv.17744

20. Larson V, Seidenberg R, Caplan A et al (2022) Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol 49:34–41. https://doi.org/10.1111/cup.14104

21. Cavalli G, Colafrancesco S, De Luca G et al (2021) Cutaneous vasculitis following COVID-19 vaccination. Lancet Rheumatol 3:e743–e744. https://doi.org/10.1016/S2665-9913(21)00309-X

22. Capassoni M, Ketabchi S, Cassissa A et al (2021) AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report. J Med Virol 93:5718–5720. https://doi.org/10.1002/jmv.27175

23. Theodorou DJ, Theodorou SJ, Axiotis A et al (2021) COVID-19 vaccine-related myositis. QJM 114:424–425. https://doi.org/10.1093/qjmed/hcb043

24. Kaulen LD, Dubroviniskaia S, Mooshage C et al (2022) Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series. Eur J Neurol 29:555–563. https://doi.org/10.1111/ejn.15147

25. Ramalingam S, Arora H, Lewis S et al (2021) COVID-19 vaccine-induced cellulitis and myositis. Cleve Clin J Med 88:648–650. https://doi.org/10.3949/ccjm.88a.21038

26. Vutipongsatorn K, Isaacs A, Farah Z (2022) Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports. J Med Case Rep 16:57. https://doi.org/10.1186/s13256-022-03266-1

27. Connolly CM, Ruddy JA, Boysarcky BJ et al (2022) Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. Arthritis Rheumatol 74:28–32. https://doi.org/10.1002/art.41924

28. Tzioufas AG, Bakasis A-D, Goules AV et al (2021) A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. J Autoimmun 125:102743. https://doi.org/10.1016/j.jaut.2021.102743

29. Fan Y, Geng Y, Wang Y et al (2021) Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2021-221736

30. Venerito V, Stefanizzi P, Fornaro M et al (2022) Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. RMD Open 8:e001847. https://doi.org/10.1136/rmdopen-2022-001847
31. Bartels LE, Damitzbøll C, Andersen JB et al (2021) Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. Rheumatol Int 41:1925–1931. https://doi.org/10.1007/s00296-021-04972-7
32. Fornaro M, Venerito V, Iannone F, Cacciapaglia F (2022) Safety Profile and low risk of disease relapse after BNT162b2 mRNA SARS-CoV-2 vaccination in patients with rare rheumatic diseases. J Rheumatol. https://doi.org/10.3899/jrheum.210863
33. Furer V, Eviatar T, Zisman D et al (2021) Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann Rheum Dis 80:1330–1338. https://doi.org/10.1136/annrheumdis-2021-220647
34. Cherian S, Paul A, Ahmed S et al (2021) Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. Rheumatol Int 41:1441–1445. https://doi.org/10.1007/s00296-021-04917-0
35. Rotondo C, Cantatore FP, Fornaro M et al (2021) Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: a two-centers study. Vaccines (Basel) 9:730. https://doi.org/10.3390/vaccines9070730
36. Pinte L, Negoi F, Ionescu GD et al (2021) COVID-19 vaccine does not increase the risk of disease flare-ups among patients with autoimmune and immune-mediated diseases. J Pers Med 11:1283. https://doi.org/10.3390/jpm11121283
37. Wack S, Patton T, Ferris LK (2021) COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol 85:1274–1284. https://doi.org/10.1016/j.jaad.2021.07.054
38. Shinjo SK, de Souza FHC, Borges IBP et al (2021) Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keab773
39. Jena A, Mishra S, Deepak P et al (2022) Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev 21:102927. https://doi.org/10.1016/j.autrev.2021.102927
40. Ferri C, Ursini F, Gragnani L et al (2021) Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups. J Autoimmun 125:102744. https://doi.org/10.1016/j.jaut.2021.102744
41. Fung M, Babik JM (2020) COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa863
42. Spinelli FR, Favalli EG, Garufi C et al (2022) Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. Arthritis Res Ther 24:21. https://doi.org/10.1186/s13075-021-02674-w

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.